Akiram Therapeutics

Private

UppsalaHealthcare & Life Scienceshttps://akiramtherapeutics.se

Last Round

Grant

Nov 24, 2023

Est. Valuation

$12.31M

Total Funding Raised

$7.1M

Company Overview

Akiram Therapeutics is a biotechnology company that develops innovative and targeted molecular radiotherapy for patients with incurable cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

targeted radioimmunotherapyradioligand therapyradiopharmaceuticalantibody platformCD44v6 targettargeted radionuclide therapysolid tumorsoncology therapeuticsprecision medicineLutetium-177nuclear medicinemetastatic cancerclinical-stage biotechalpha-therapeuticshead and neck cancer

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Akiram Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Akiram Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Nov 24, 2023
Series A	Jan 12, 2023

View all Funding Rounds

Key People

Founding team and executive leadership

Anja Lundgren Mortensen

Chief Technology Officer

Executive Team

Akiram Therapeutics Investors

Notable investors and investment history

Investor	Rounds
Sciety	Series A
Erling-Persson Foundation	Grant
Linc AB	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Oct 4, 2025
Attending EANM Congress 2025 in Barcelona from October 4-8.
Apr 3, 2025
Partnered with PreTT and TetraKit Technologies on targeted radiotherapy.

View all signals

Akiram Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Akiram Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Akiram Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersUppsala

Employee Range6

Year Founded2021

Last FundingNov 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.